https://hmjournals.com/ijaap/index.php/JHTD/issue/feed 2025-06-30T10:56:40+00:00 Editor in Chief editorincheif.jhtd@gmail.com Open Journal Systems <p>The<strong> Journal Healthcare Treatment Development(JHTD</strong>) having <strong>ISSN:2799-1148</strong> is a double-blind, peer-reviewed, open access journal that provides publication of articles in all areas of Healthcare, medical and related disciplines. The objective of this journal is to provide a veritable platform for scientists and researchers all over the world to promote, share, and discuss a variety of innovative ideas and developments in all aspects of<strong> Healthcare and medical</strong></p> https://hmjournals.com/ijaap/index.php/JHTD/article/view/5042 2024-12-07T10:01:35+00:00 Afshana Qadir qadirafshana3@gmail.com Mohd Altaf Dar qadirafshana3@gmail.com Zulfkar Qadrie qadirafshana3@gmail.com Humaira Ashraf qadirafshana3@gmail.com

<p>Cancer remains one of the most challenging health issues worldwide, necessitating continual advancements in management strategies. Current management of cancer involves a multimodal approach, integrating surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapies. Surgery and radiation therapy are often employed to remove or shrink tumors, while chemotherapy is used to destroy cancer cells throughout the body. In recent years, immunotherapy, which harnesses the body's immune system to fight cancer, has gained prominence, particularly in treating cancers those are resistant to traditional therapies. Targeted therapies represent another significant advancement, focusing on specific molecular targets associated with cancer growth and survival. These therapies have shown success in treating cancers with particular genetic mutations, such as HER2-positive breast cancer and EGFR-mutated lung cancer. However, challenges such as drug resistance and toxicity remain, prompting the need for continued research. The future of cancer treatment is increasingly centered on precision medicine, which tailors treatments to the genetic profile of individual patients and their tumors. Precision medicine aims to improve outcomes by identifying the most effective therapies for each patient based on their unique genetic makeup. This approach has already led to the development of personalized treatment plans that target specific mutations or pathways involved in cancer progression.</p>

2024-12-07T00:00:00+00:00 Copyright (c) 2024 Authors https://hmjournals.com/ijaap/index.php/JHTD/article/view/5653 2025-06-30T10:56:40+00:00 Eseka K kenneth.eseka@unidel.edu.ng Prof. Mokobia C E mokobia@delsu.edu.ng Akpolile F. A akpolileaf@delsu.edu.ng Dr. Illugo N.T nwanne.ilugo@unidel.edu.ng Egheneji A anthony.egheneji@unidel.edu.ng

<p>This study evaluates radiation dose levels in adult chest and abdomen CT procedures using Size-Specific Dose Estimates (SSDE) across selected CT centers in Rivers and Delta States. The data was analyzed using de-identified data from console records to ensure confidentiality. The study found that female patients had a more significant percentage of CT chest scans (54.30%) and abdominal scans (59.86%) than males. The patient group showed a wide age range (18 to 93 years). Adjustments in tube voltage and current intensity were indicated for patient size and imaging requirements. For chest scans, radiation exposure averaged 50.04 mGy (±11.34) and 523.2 mGy.cm (±112.33), while for abdomen scans, the average was 58.12 mGy (±19.58) and 725.81 mGy.cm (±114.07). ANOVA results revealed a significant association between age and dose-area product (DAP TRANS) for both chest and abdomen scans. Consistent scan settings remained constant across age categories, implying consistent scan settings irrespective of patient age. These findings emphasize the impact of patient demographics on CT scan parameters and radiation exposure, highlighting the need for individualized dose optimization strategies.</p>

2025-06-26T00:00:00+00:00 Copyright (c) 2025 Authors